Search

Now showing items 1-4 of 4

Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis - A 2-year follow-up

Van Rensburg C.J.; Honiball P.J.; Van Zyl J.H.; De Grundling H.K.; Eloff F.P.; Spies S.K.; Simjee A.E.; Theron I.; Fischer R.; Louw J.A. (1999)

Background: Pantoprazole is a benzimidazole derivative which selectively inhibits the proton pump H+, K+-ATPase, necessary for the final step in gastric acid secretion. Aim: To assess safety and efficacy of oral pantoprazole ...

Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis

Van Rensburg C.J.; Honiball P.J.; Grundling H.D.K.; Van Zyl J.H.; Spies S.K.; Eloff F.P.; Simjee A.E.; Segal I.; Botha J.F.; Cariem A.K.; Marks I.N.; Theron I.; Bethke T.D. (1996)

Background: Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K+-ATPase. Methods: Pantoprazole 40 mg and 80 mg were compared in a randomized double-blind ...

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study

Hawkey C.J.; Tulassay Z.; Szczepanski L.; Van Rensburg C.J.; Filipowicz-Sosnowska A.; Lanas A.; Wason C.M.; Peacock R.A.; Gillon K.R.W. (1998)

Background. The effect of Helicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) is unclear. We investigated the effects of H pylori eradication in patients with current or previous peptic ...

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs

Yeomans N.D.; Tulassay Z.; Juhasz L.; Racz I.; Howard J.M.; Van Rensburg C.J.; Swannell A.J.; Hawkey C.J. (1998)

Background: Suppressing acid secretion is thought to reduce the risk of ulcers associated with regular use of nonsteroidal antiinflammatory drugs (NSAIDs), but the best means of accomplishing this is uncertain. Methods: ...